See All of This Company's Exhibits Find More Exhibits Like This

EX-4.4 4 exhibit441.htm EX-4.4 Innate Pharma SA - Amendment No. 9 to Joint Research, Development, Option and License Agreement between Innate Pharma S.A. and Novo Nordisk A/S dated March 28, 2006, dated July 18, 2024

AMENDMENT N°. 9

This Amendment No. 9 (the “Amendment”) is made and entered into as of July 18th 2024 (“Effective Date”) between Innate Pharma SA, a corporation existing under the laws of France (“IPH”) and Novo Nordisk A/S, a corporation existing under the laws of Denmark (“NN”) with regards to the Joint Research, Development, Option and License Agreement dated March 28, 2006, as amended by Amendment and Supplement No.1, dated October 8, 2008, Amendment and Supplement No. 2, dated October 8, 2008, Amendment and Supplement No. 3, dated June 26, 2009, Amendment No. 4, dated December 13, 2010, Amendment No. 5, dated December 13, 2010, Amendment 6 dated July 1st 2011, Amendment and Supplement No. 7 dated February 5, 2014 and Amendment and Supplement No. 8 dated September 16 2016 (collectively, the “Agreement”). NN and IPH may each individually be referred to as “Party” and collectively as “Parties”.

Whereas pursuant to the Agreement, NN and IPH agreed to work, independently, jointly and/or together with agreed-upon Third Parties, to (a) discover or identify Drug Candidates, and (b) optimize Drug Candidates for progression to (i) Licensed Products for further development and commercialization by NN or (ii) Niche Candidates for further development and commercialization by IPH (either alone or together with NN), in each case for all uses and purposes, including therapeutic, prophylactic and, except as otherwise expressly therein provided, diagnostic uses;

Whereas pursuant to Amendment No.1 and with effect from Amendment No.1 Effective Date, NN classified Anti-KIR as a Niche Candidate for independent further development and commercialization by IPH for any human therapeutic, prophylactic or diagnostic indication or application;

Whereas as a condition precedent to its entry into a license agreement with IPH pursuant to which Bristol-Myers Squibb Company (“BMS”) became an Out-licensee under the Agreement (the “Out-licensee”), the Parties have executed Amendment No 6 on July 1st 2011 clarifying certain matters with respect to the rights and obligations of the Parties and of BMS with respect to Anti-KIR; and

Whereas Anti-Kir or Anti-Kir Antibodies were licensed-out by IPH to BMS under a Collaboration and License Agreement dated July 6th 2011 (the “ BMS COLA”);

Whereas The development of lirilumab and other Anti-Kir or Anti-Kir Antibodies in a number of Phase I and II clinical trials sponsored by NN, IPH and/or BMS ended in 2017 for lack of clinical efficacy in Phase 2 trials in several tumor types including Acute Myeloid Leukemia and Head and Neck cancer;

Whereas IPH and BMS would like to terminate their Collaboration and License Agreement and are contemplating the abandonment of all IP rights, patents, regulatory material and more globally all information related to Anti-Kir or Anti-Kir Antibodies;
Now, therefore, the Parties, intending to be legally bound, agree as follows:

1.The terms defined in the Agreement shall have the meaning herein, unless otherwise defined herein or unless the context otherwise requires. To the extent that the Agreement is explicitly amended by this Amendment, the terms of the Amendment will control where the terms of the Agreement are contrary to or conflict with the following provisions. Where the Agreement is not explicitly amended by this Amendment, the terms of the Agreement will remain in force.

2.The Parties hereby acknowledge that the BMS COLA has been terminated with BMS ceasing to be an Out-Licensee as of July 18th 2024.

3.With effect from the Effective Date, the Parties hereby agree to partially terminate the JRDOLA with respect to Anti-Kir, Anti-Kir Product or Anti-Kir Antibodies.

4.As a consequence all rights and obligations of the Parties are terminated with respect to Anti-Kir, Anti-Kir Product or Anti-Kir Antibodies as from the Effective Date and each Party hereby waive any rights such Party may have on the Anti-Kir or Anti-Kir Antibodies IP rights, Anti-KIR Patents, regulatory material and more globally all information related to Anti-Kir, Anti-Kir Product or Anti-Kir Antibodies;

5.The Anti-KIR Patents (including Shared Anti-KIR Patents) are listed in Appendix 1.

6.BMS and IPH intends to discontinue the prosecution, maintenance and defense of the Shared Anti-KIR Patents.



7.NN acknowledges BMS and IPH intention to abandon such Shared Anti-KIR Patents and hereby similarly abandon its rights to file, defend, maintain or continue prosecution of any of such Shared Anti-KIR Patent, at its own expense.

8.NN acknowledges that University of Genoa may choose to file, defend, maintain or continue prosecution of any of such Shared Anti-KIR Patent in which it has ownership rights.

9.Further, neither BMS nor IPH shall have any obligation to transfer back any IP right, patent or regulatory material, clinical data and more globally all information related to Anti-Kir, Anti-Kir Product or Anti-Kir Antibodies to NN.

10.All and any remaining payment obligations, if any, with regard to Anti-Kir, Anti-Kir Product or Anti-Kir Antibodies are hereby terminated.

11.Each Party hereby waives all rights it may have under the Agreement on any Collaborative IPR, Collaboration Research Technology IPR, Collaboration Patent or Collaboration Know-How on Anti-Kir, Anti-Kir Product or Anti-Kir Antibodies and hereby declares and warrants that it will not continue to maintain any Collaboration Patent on Anti-Kir, Anti-Kir Product or Anti-Kir Antibodies. Any intellectual property that might have been created jointly by the Parties and/or that is defined as Collaborative IPR, Collaboration Research Technology IPR, Collaboration Patent or Collaboration Know-How on Anti-Kir, Anti-Kir Product or Anti-Kir Antibodies will become part of the public domain.

As a consequence, each Party may conduct research on Anti-Kir or Anti-Kir Antibodies. Any new invention or new intellectual property rights that may arise after the Effective Date from such research activities performed individually by either party will be the property of the Party having conducted the research with no right nor any obligation to the others.

12.Each Party hereby waives any action it may have against the other based on or related to Anti-Kir, Anti-Kir Product or Anti-Kir Antibodies rights and obligations as provided by the JRDOLA.

13.This Amendment shall be deemed an integral part of the Agreement. Except as expressly set forth herein, all provisions of the Agreement shall remain unchanged and in full force and effect. The Parties expressly affirm their mutual intention that this Amendment to the Agreement shall constitute a legally binding Amendment to the Agreement.

This Amendment shall be construed and interpreted pursuant to the laws stipulated in the Agreement. All disputes arising out of or in connection with this Amendment N°9 shall be settled by arbitration as provided by the Agreement.

IN WITNESS WHEREOF, the Parties have executed and delivered this Amendment.



On behalf of Innate Pharma SA     On behalf of NovoNordisk A/S

Signature: s/ Yannis Morel                Signature: s/ Karin Conde-Knape







Attachment 1


Part A – Anti-KIR Patents

1. Cross-reactive anti-KIR antibodies. Applicant/owner: NN, IPH, and University of Genoa (UG).
IPH Ref.NN Ref.Application No.
Filing date		TitleStatus
Kirostim NN 68036803.204-WOPCT/DK2004/00470
1-Jul-2004		Compositions and methods for regulating NK cell activityPublished as WO2005/003168
National phase entered
Idem6803.205.EPEP 04738967.1
1-Jul-2004		IdemGranted
Idem6803.204-BRBR PI 0412153-8
1-Jul-2004		IdemGranted
Idem6803.204-CNCN 200480021897.0
1-Jul-2004		IdemGranted
IdemCN 2014108318900Abandoned
Idem6803.204-ILIL 172700
1-Jul-2004		IdemGranted
Idem6803.204-JPJP 2006-515738
1-Jul-2004		IdemGranted
Idem6803.204-ININ5990/DELNP/2005
1-Jul-2004		IdemGranted
Idem6803.204-CACA 2530272
1-Jul-2004		IdemGranted
Idem6803.204-KRKR 2006-7000025
1-Jul-2004		IdemGranted
Idem6803.204-ZAZA 2006/00792
1-Jul-2004		IdemGranted
Idem6803.204-AUAU 2004253630
1-Jul-2004		IdemGranted
Idem6803.204-USUS 11/324356
1-Jul-2004		IdemGranted
Idem12/847,090IdemGranted
Idem14/789,548IdemGranted
Idem6803.204-RURU 2005140152
1-Jul-2004		IdemGranted
Idem6803.204-NONO 20060528
1-Jul-2004		IdemGranted
Idem6803.204-MXMX 2005/014074
1-Jul-2004		IdemGranted

2. Human anti-KIR antibodies, including Anti-KIR(1-7F9). Applicant/owner: NN, IPH, and UG.
IPH Ref.NN Ref.Application No.
Filing date		TitleStatus
Kirostim NN 7121-5047121.000-DKDK PA 2005 00025
6-Jan-2005		Human anti-KIR antibodiesExpired
Idem7121.003-USUS 60/642,808
11-Jan-2005		IdemExpired
Idem7121.504-WOPCT/EP2005/053122
1-Jul-2005		IdemPublished as WO2006/003179
National phase entered
Idem7121.504-TWTW 94122367
1-Jul-2005		IdemGranted
Idem7121.505-EPEP 05758642.2
1-Jul-2005		IdemGranted
EP 10178924.6
Idem7121.504-AUAU 2005259221
1-Jul-2005		IdemGranted
Idem7121.504-BRBR 2004PI12138
1-Jul-2005		IdemGranted
Idem7121.504-CACA 2601417
1-Jul-2005		IdemGranted
Idem7121.504-CNCN 200580022633.1
1-Jul-2005		IdemGranted
Idem7121.504-ILIL 179635
1-Jul-2005		IdemGranted
Idem7121.504-ININ7162/DELNP/2006
1-Jul-2005		IdemGranted
Idem7121.504-JPJP 2007518617
1-Jul-2005		IdemGranted
Idem7121.504-KRKR 10-2007-7000069
1-Jul-2005		IdemGranted


Idem7121.504-MXMX a/2007/000210
1-Jul-2005		IdemGranted
Idem7121.504-NONO 20070585
1-Jul-2005		IdemGranted
Idem7121.504-RURU 2006144820
1-Jul-2005		IdemGranted
Idem7121.504-USUS 11/630176
1-Jul-2005		IdemAbandoned
IdemUS 12/244,170IdemGranted
IdemUS 13/347,832IdemGranted
IdemUS 13/936,486IdemGranted
Idem7121.504-ZAZA 2007/00736
1-Jul-2005		IdemGranted

3. Treatment of viral infection. Applicant/owner: NN and IPH.
IPH Ref.NN Ref.Application No.
Filing date		TitleStatus
Kirostim NN 68746874.000-DKDK PA 2005 00027
6-Jan-2005		Treatment of viral infectionExpired
Idem6874.003-USUS 60/646,717
25-Jan-2005		IdemExpired
Idem6874.204-WOPCT/EP2006/050071
6-Jan-2006		IdemPublished as WO2006/072624
National phase entered
Idem6874.205-EPEP 06700714.6
6-Jan-2006		IdemGranted
Idem6874.204-JPJP 2007-549894
6-Jan-2006		IdemGranted
IdemUS 14/043,402IdemGranted
Idem6874.204-USUS 11/813,399
6-Jan-2006		IdemGranted

4. Anti-KIR combination treatments. Applicant/owner: NN and IPH.
IPH Ref.NN Ref.Application No.
Filing date		TitleStatus
Kirostim NN 68986898.000-DKDK PA 2005 00026
6-Jan-2005		Anti-KIR combination treatmentExpired
Idem6898.003-USUS 60/642,128
7-Jan-2005		IdemExpired
Idem6898.204-WOPCT/EP2006/050072
6-Jan-2006		IdemPublished as WO2006/072625
National phase entered
Idem6898.205-EPEP 06700713.8
6-Jan-2006		IdemGranted
IdemEP 16167879.2IdemGranted
Idem6898.204-JPJP 2007-549895
6-Jan-2006		IdemGranted
IdemJP 2014-023776
IdemGranted
Idem6898.204-USUS 13/183,602
15-Jul-2011		IdemGranted

5. Non-competitive antagonist KIR-binding agents. Applicant/owner: Novo Nordisk and Innate-Pharma.
IPH Ref.NN Ref.Application No.
Filing date		TitleStatus
Kirostim NN 69236923.000-DKDK PA 2005 00021
6-Jan-2005		Agents that block KIR-KIR interactionsExpired
Idem6923.003-USUS 60/642,646
10-Jan-2005		IdemExpired
Idem6923.204-WOPCT/EP2006/050073
6-Jan-2006		KIR-binding agents and methods of use thereofPublished as WO2006/072626
National phase entered
Idem6923.204-CNCN 200680001919.6
6-Jan-2006		IdemAbandoned
IdemCN 201510214401.1Granted
Idem6923.205-EPEP 2006701729.3
6-Jan-2006		IdemGranted
Idem6923.204-ININ 4447/DELNP/2007
6-Jan-2006		IdemGranted
Idem6923.204-JPJP 2007-549896
6-Jan-2006		IdemGranted
Idem6923.204-USUS 11/813402
6-Jan-2006		IdemGranted
IdemUS 12/244,101IdemGranted


IdemUS 13/745,081IdemGranted
IdemUS 14/665,731IdemGranted

6. Formulations and dosages of containing Anti-KIR antibodies. Applicant/Owner: Novo Nordisk.
IPH Ref.NN Ref.Application No.
Filing date		TitleStatus
KIROSTIM NN 75757575.000-USUS 60/879964
11-Jan-2007		Anti-KIR antibodies, formulations, and uses thereofExpired
Idem7575.010-USUS 60/911527
13-Apr-2007		IdemExpired
Idem7575.204-WOPCT/EP2008/050306
11-Jan-2008		IdemPublished as WO2008/084106
IdemAU 2008204433IdemGranted
IdemAU 2013237638IdemGranted
IdemCA 2,675,291IdemGranted
IdemCN 200880002001.2IdemGranted
IdemCN 2015101427263IdemGranted
IdemEP 08707869.7IdemGranted
IdemEP 13159380.8IdemGranted
IdemJP 2013-213757IdemGranted
IdemUS 14/606,814IdemGranted
IdemUS 15/849,128IdemGranted

7. Anti-NKG2A (and other receptors) mAbs for inflammatory indications. Applicant/Owner: IPH, UG and NN.
IPH Ref.NN Ref.Application No.
Filing date		TitleStatus
LDGL-CIPINNA-051014-WOPCT/EP2006/067399
13-Oct-2006		Compositions and Methods for treating Proliferative DisordersPublished as WO2007/042573
National phase entered
IdemINNA-051014-USUS 12/089,314
4-Apr-2008
IdemGranted
IdemINNA-051014-AUAU 200630116
13-Oct-2006		IdemGranted
IdemINNA-051014-CACA 2,623,109
13-Oct-2006		IdemGranted
IdemINNA-051014-CNCN 200680038141.6
13-Oct-2006		IdemGranted
IdemINNA-051014-EPEP 06 807262.8
13-Oct-2006		IdemGranted
IdemEP 11150593.9IdemGranted
IdemINNA-051014-JPJP 2008-535041
13-Oct-2006		IdemGranted

8. Antibodies, antibody fragments, and derivatives thereof that cross-react with two or more inhibitory receptors (KIR2DL1 and KIR2DL2,3) present on the cell surface of NK cells, and which potentiate NK cell cytotoxicity in mammalian subjects or in a biological sample. Applicant/owner: IPH and UG.
IPH Ref.NN Ref.Application No.
Filing date		TitleStatus
KirostimINNA-030702-I-USUS 60/483,894
07/02/2003
Compositions and methods for regulating NK cell activityExpired
IdemINNA-030702-I-US1US 60/545,471
02/19/2004
IdemExpired
IdemINNA-030702-I-WOPCT/IB2004/002464
07/01/2004		IdemPublished as WO2005/003172
National phase entered
IdemINNA-030702-I-US3US 10/563,045
12/30/2005		IdemGranted
US 15/876,839IdemGranted
IdemINNA-030702-I-AUAU 2004253770
07/01/2004		PAN-KIR2DL NK-Receptor Antibodies and their Use in Diagnostic and TherapyGranted
IdemINNA-030702-I-BRBR PI 0412138-4
07/01/2004		IdemGranted
IdemINNA-030702-I-CACA 2,530,591
07/01/2004		IdemGranted
IdemINNA-030702-I-CNCN 200480024006.7
07/01/2004		IdemGranted
IdemINNA-030702- I-EPEP 04 744115.9
07/01/2004		IdemGranted


EP 10178580.IdemGranted
IdemINNA-030702-I-HKHK 06108029.2
07/18/2006		IdemGranted
IdemINNA-030702-I-ILIL 172613
07/01/2004		IdemGranted
IdemINNA-030702-I-ININ5904/DELNP/2005
07/01/2004		IdemGranted
IdemINNA-030702-I-JPJP 2006-516606
07/01/2004		IdemGranted
IdemINNA-030702-I-KRKR 10-2006-7000109
07/01/2004		IdemGranted
IdemINNA-030702-I-MXMX PA/a/2005013923
07/01/2004		IdemGranted
IdemINNA-030702-I-NONO 2005 6048
07/01/2004		IdemGranted
IdemINNA-030702-I-RURU 2006102960
07/01/2004		IdemGranted
IdemINNA-030702-I-ZAZA 2006/0842
07/01/2004		IdemGranted

9. Use of blocking anti-NKG2A and -KIR mAbs (as well as anti-NCR mAbs) in combination with depleting mAbs, where the anti-NKG2A mAb-mediated NK cell activation may enhance ADCC toward a target cell. Applicant/owner: IPH. Subject to Patent Assignment agreement of February 2006 between IPH and the University of Perugia).
IPH Ref.NN Ref.Application No.
Filing date		TitleStatus
Anti-KIR/ ADCCINNA-030724-USUS 60/489,489
07/24/2003
Methods and compositions for increasing the efficiency of therapeutic antibodies using compounds that block the inhibitory receptors of NK cellsExpired
IdemINNA-030724-WOPCT/IB 2004/02636
07/23/2004		IdemPublished as
WO2005/009465
National phase entered
IdemINNA-030724-US1US 10/897,624
07/23/2004		IdemGranted
IdemUS 12/847,090IdemGranted
IdemUS 14/789,548IdemGranted
IdemINNA-030724-AUAU 2004258747
07/23/2004		IdemGranted
IdemINNA-030724-BRBR PI 041 2890-7
07/23/2004		IdemGranted
IdemINNA-030724-CA 2,532,54
07/23/2004		IdemGranted
IdemINNA-030724-CNCN 200480021421.
07/23/2004		IdemAbandoned
IdemCN 201110414480.2IdemGranted
IdemINNA-030724-EPEP 04 744267.8
07/23/2004		IdemGranted
IdemINNA-030724-HKHK 06108031.8
07/18/2006		IdemGranted
IdemINNA-030724-ININ5934/DELNP/2005
07/23/2004		IdemGranted
IdemIN 2422/DELNP/2008IdemGranted
IdemINNA-030724-ILIL 172679IdemGranted
IdemINNA-030724-JPJP 2006-520938
07/23/2004		IdemGranted
IdemJP 2011-201631IdemGranted
IdemJP 2014-181655IdemGranted
IdemINNA-030724-KRKR 10-2006-7001698
07/23/2004		IdemGranted
KR 10-2012-7014089IdemGranted
IdemINNA-030724-MXMX PA/a/2006/000841
07/23/2004		IdemGranted
IdemINNA-030724-NONO 2005 6049
07/23/2004		IdemGranted
IdemNO 20150493IdemGranted
IdemINNA-030724-RURU 2006105642
07/23/2004		IdemGranted
IdemINNA-030724-ZAZA 2006/1584
07/23/2004		IdemIssued

10. Use of depleting anti-NKG2A (and other NK receptor) mAbs for the treatment of LGL and other suitable and/or related diseases including T-cell type LDGL, autoimmune disorders, and any other immunoproliferative or malignant disorders involving NK or other NKG2A-expressing lymphocytes. Applicant/owner: IPH and UG.


IPH Ref.NN Ref.Application No.
Filing date		TitleStatus
LDGL
INNA-040430-B-USUS 60/567,329
04/30/2004		Compositions and Methods for treating Proliferative DisordersExpired
IdemINNA-040430-B-WOPCT/IB2005/001494
04/29/2005		IdemPublished as WO2005/105849
National phase entered
IdemINNA-040430-B-US1US 11/587,892 10/27/2006IdemAbandoned
IdemINNA-040430-B-AUAU 2005238300
04/29/2005		IdemAbandoned
IdemINNA-040430-B-EPEP 05 739838.0 04/29/2005IdemAbandoned
IdemINNA-040430-B-CACA 2,564,246
04/29/2005		IdemAbandoned
IdemINNA-040430-B-JPJP 2007-510158
04/29/2005		IdemAbandoned

Part B – Shared Anti-KIR Patents

1. Cross-reactive anti-KIR antibodies. Applicant/owner: NN, IPH, and University of Genoa (UG).
IPH Ref.NN Ref.Application No.
Filing date		TitleStatus
Kirostim NN 68036803.204-WOPCT/DK2004/00470
1-Jul-2004		Compositions and methods for regulating NK cell activityPublished as WO2005/003168
National phase entered
Idem6803.205.EPEP 04738967.1
1-Jul-2004		IdemGranted
Idem6803.204-BRBR PI 0412153-8
1-Jul-2004		IdemGranted
Idem6803.204-CNCN 200480021897.0
1-Jul-2004		IdemGranted
IdemCN 2014108318900Abandoned
Idem6803.204-ILIL 172700
1-Jul-2004		IdemGranted
Idem6803.204-JPJP 2006-515738
1-Jul-2004		IdemGranted
Idem6803.204-ININ5990/DELNP/2005
1-Jul-2004		IdemGranted
Idem6803.204-CACA 2530272
1-Jul-2004		IdemGranted
Idem6803.204-KRKR 2006-7000025
1-Jul-2004		IdemGranted
Idem6803.204-ZAZA 2006/00792
1-Jul-2004		IdemGranted
Idem6803.204-AUAU 2004253630
1-Jul-2004		IdemGranted
Idem6803.204-USUS 11/324356
1-Jul-2004		IdemGranted
Idem12/847,090IdemGranted
Idem14/789,548IdemGranted
Idem6803.204-RURU 2005140152
1-Jul-2004		IdemGranted
Idem6803.204-NONO 20060528
1-Jul-2004		IdemGranted
Idem6803.204-MXMX 2005/014074
1-Jul-2004		IdemGranted

2. Human anti-KIR antibodies, including Anti-KIR(1-7F9). Applicant/owner: NN, IPH, and UG.
IPH Ref.NN Ref.Application No.
Filing date		TitleStatus
Kirostim NN 7121-5047121.000-DKDK PA 2005 00025
6-Jan-2005		Human anti-KIR antibodiesExpired
Idem7121.003-USUS 60/642,808
11-Jan-2005		IdemExpired
Idem7121.504-WOPCT/EP2005/053122
1-Jul-2005		IdemPublished as WO2006/003179
National phase entered
Idem7121.504-TWTW 94122367
1-Jul-2005		IdemGranted
TW 101113099IdemGranted
Idem7121.505-EPEP 05758642.2
1-Jul-2005		IdemGranted
EP 10178924.6IdemGranted


Idem7121.504-AUAU 2005259221
1-Jul-2005		IdemGranted
Idem7121.504-BRBR 2004PI12138
1-Jul-2005		IdemGranted
Idem7121.504-CACA 2601417
1-Jul-2005		IdemGranted
Idem7121.504-CNCN 200580022633.1
1-Jul-2005		IdemGranted
Idem7121.504-ILIL 179635
1-Jul-2005		IdemGranted
Idem7121.504-ININ7162/DELNP/2006
1-Jul-2005		IdemAbandoned
Idem7121.504-JPJP 2007518617
1-Jul-2005		IdemGranted
JP 2012-176067IdemGranted
Idem7121.504-KRKR 10-2007-7000069
1-Jul-2005		IdemGranted
Idem7121.504-MXMX a/2007/000210
1-Jul-2005		IdemGranted
Idem7121.504-NONO 20070585
1-Jul-2005		IdemGranted
NO 20171133IdemGranted
Idem7121.504-RURU 2006144820
1-Jul-2005		IdemGranted
Idem7121.504-USUS 11/630176
1-Jul-2005		IdemGranted
US 12/244,170IdemGranted
US 13/347,832IdemGranted
US 13/936,486IdemGranted
Idem7121.504-ZAZA 2007/00736
1-Jul-2005		IdemGranted

3. Treatment of viral infection. Applicant/owner: NN and IPH.
IPH Ref.NN Ref.Application No.
Filing date		TitleStatus
Kirostim NN 68746874.000-DKDK PA 2005 00027
6-Jan-2005		Treatment of viral infectionExpired
Idem6874.003-USUS 60/646,717
25-Jan-2005		IdemExpired
Idem6874.204-WOPCT/EP2006/050071
6-Jan-2006		IdemPublished as WO2006/072624
National phase entered
Idem6874.205-EPEP 06700714.6
6-Jan-2006		IdemGranted
Idem6874.204-JPJP 2007-549894
6-Jan-2006		IdemGranted
IdemUS 14/043,402IdemGranted
Idem6874.204-USUS 11/813,399
6-Jan-2006		IdemGranted



4. Anti-KIR combination treatments. Applicant/owner: NN and IPH.
IPH Ref.NN Ref.Application No.
Filing date		TitleStatus
Kirostim NN 68986898.000-DKDK PA 2005 00026
6-Jan-2005		Anti-KIR combination treatmentExpired
Idem6898.003-USUS 60/642,128
7-Jan-2005		IdemExpired
Idem6898.204-WOPCT/EP2006/050072
6-Jan-2006		IdemPublished as WO2006/072625
National phase entered
Idem6898.205-EPEP 06700713.8
6-Jan-2006		IdemGranted
IdemEP 16167879.2IdemGranted
Idem6898.204-JPJP 2007-549895
6-Jan-2006		IdemGranted
IdemJP 2014-023776
IdemGranted
Idem6898.204-USUS 13/183,602
15-Jul-2011		IdemGranted





5. Non-competitive antagonist KIR-binding agents. Applicant/owner: Novo Nordisk and Innate-Pharma.
IPH Ref.NN Ref.Application No.
Filing date		TitleStatus
Kirostim NN 69236923.000-DKDK PA 2005 00021
6-Jan-2005		Agents that block KIR-KIR interactionsExpired
Idem6923.003-USUS 60/642,646
10-Jan-2005		IdemExpired
Idem6923.204-WOPCT/EP2006/050073
6-Jan-2006		KIR-binding agents and methods of use thereofPublished as WO2006/072626
National phase entered
Idem6923.204-CNCN 200680001919.6
6-Jan-2006		IdemAbandoned
IdemCN 201510214401.1Granted
Idem6923.205-EPEP 2006701729.3
6-Jan-2006		IdemGranted
Idem6923.204-ININ 4447/DELNP/2007
6-Jan-2006		IdemGranted
Idem6923.204-JPJP 2007-549896
6-Jan-2006		IdemGranted
Idem6923.204-USUS 11/813402
6-Jan-2006		IdemGranted
IdemUS 12/244,101IdemGranted
IdemUS 13/745,081IdemGranted
IdemUS 14/665,731IdemGranted


6. Formulations and dosages of containing Anti-KIR antibodies. Applicant/Owner: Novo Nordisk.
IPH Ref.NN Ref.Application No.
Filing date		TitleStatus
KIROSTIM NN 75757575.000-USUS 60/879964
11-Jan-2007		Anti-KIR antibodies, formulations, and uses thereofExpired
Idem7575.010-USUS 60/911527
13-Apr-2007		IdemExpired
Idem7575.204-WOPCT/EP2008/050306
11-Jan-2008		IdemPublished as WO2008/084106
IdemAU 2008204433IdemGranted
IdemAU 2013237638IdemGranted
IdemCA 2,675,291IdemGranted
IdemCN 200880002001.2IdemGranted
IdemCN 2015101427263IdemGranted
IdemEP 08707869.7IdemGranted
IdemEP 13159380.8IdemGranted
IdemJP 2013-213757IdemGranted
IdemUS 14/606,814IdemGranted
IdemUS 15/849,128IdemGranted


7. Anti-NKG2A (and other receptors) mAbs for inflammatory indications. Applicant/Owner: IPH, UG and NN.

IPH Ref.NN Ref.Application No.
Filing date		TitleStatus
LDGL-CIPINNA-051014-WOPCT/EP2006/067399
13-Oct-2006		Compositions and Methods for treating Proliferative DisordersPublished as WO2007/042573
National phase entered
IdemINNA-051014-USUS 12/089,314
4-Apr-2008
IdemGranted
IdemINNA-051014-AUAU 200630116
13-Oct-2006		IdemGranted
IdemINNA-051014-CACA 2,623,109
13-Oct-2006		IdemGranted
IdemINNA-051014-CNCN 200680038141.6
13-Oct-2006		IdemGranted
IdemINNA-051014-EPEP 06 807262.8
13-Oct-2006		IdemGranted
IdemEP 11150593.9IdemGranted
IdemINNA-051014-JPJP 2008-535041
13-Oct-2006		IdemGranted